Profound Medical Corp. (PROF)
Profound Medical Corp. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Mississauga, ON, CA. The stock last traded at $5.76, up 2.86% on the session, giving a market capitalisation of $209.3M. On trailing twelve-month figures it carries a trailing P/E of -5.96, a net margin of -170.9%. Its beta of 0.53 implies it has historically moved less than the broad market.
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
Profound Medical Corp. is most often compared with the following Healthcare names: